SCHEMBL2248124

SCHEMBL2248124

CC(C)(C)OC(=O)N1CCC(n2c(=O)n(CC(=O)O)c3ncccc32)CC1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 6/20 0.46
DTYMK P23919 1/20 0.43
DDB1 Q16531 1/20 0.43
CRBN Q96SW2 1/20 0.43
OPRM1 P35372 1/20 0.43
OPRD1 P41143 1/20 0.43
OGFRL1 Q5TC84 1/20 0.43
PIK3CA P42336 1/20 0.42
MTOR P42345 1/20 0.42
PRKDC P78527 1/20 0.42
POLB P06746 1/20 0.42
HCAR1 Q9BXC0 1/20 0.42
STS P08842 1/20 0.41
KDM4E B2RXH2 1/20 0.41
PKM P14618 1/20 0.41
CCR5 P51681 1/20 0.41
HPGDS O60760 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12357647 0.92 GPR119 (0.46) GPR119DTYMKDDB1CRBNOPRM1
SCHEMBL2250127 0.89 ALDH1A1 (0.47) GPR119DTYMKDDB1CRBNOPRM1
SCHEMBL8103415 0.86 OPRL1 (0.53) GPR119OPRM1STSKDM4EPKM
SCHEMBL3764320 0.85 PIK3CA (0.51) GPR119DTYMKDDB1CRBNOPRM1
SCHEMBL2251051 0.85 GPR119 (0.46) GPR119DTYMKDDB1CRBNOPRM1
SCHEMBL29712771 0.82 GPR119 (0.47) GPR119DTYMKDDB1CRBNOPRM1
SCHEMBL27100998 0.82 GPR119 (0.47) GPR119DTYMKDDB1CRBNOPRM1
SCHEMBL12357645 0.81 ALDH1A1 (0.49) GPR119DTYMKDDB1CRBNOPRM1
SCHEMBL2251115 0.80 TP53 (0.42) OPRM1OPRD1PRKDCPOLBKDM4E
SCHEMBL26671857 0.78 GPR119 (0.49) GPR119DTYMKDDB1CRBNOPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110190336-A1 AZABENZIMIDAZOLONES CARA THERAPEUTICS, INC. (US) 2011-08-04 US disclosed
WO-2010045276-A2 AZABENZIMIDAZOLONES CARA THERAPEUTICS, INC. (US) 2010-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190336-A1 AZABENZIMIDAZOLONES PTGER1, PTGDR, PTGER2 GPR119 569/4885DTYMK 2455/4885DDB1 2333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.